PreComb
Key Facts
| Invested since | 2021 |
| Based in | International |
About the company
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring precision medicine benefits to all cancer patients. PreComb is pioneering breakthrough technologies to directly test the drug response of individual cancer patients, based on patient-derived 3D microtumors. For the first time, a fully automated point-of-care solution for determining drug sensitivity or resistance directly in the clinic is being developed. This offers the unique ability to routinely test entire portfolios of cancer drugs and drug combinations in large-scale, making the technology a universal tool from drug discovery to guiding therapies.
Do you want to
know more about this company?
PreComb in the news
Zum Artikel
PreComb Therapeutics AG secures CHF 2.2 Mio seed financing to advance personalized medicine for cancer patients
More startups from Life Sciences
Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary “Explainable AI” platform draws on …
To the complete profileof Aignostics
Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer …
To the complete profileof Abalos
Preventicus GmbH is developing smartphone-driven solutions to capture and analyze patients’ vital parameters for early preclinical risk screening of lifestyle-related illnesses. Seed funding for the Jena-based company is managed by …
To the complete profileof Preventicus
Exit
Modern therapeutic approaches face the challenge to combine efficacy, low undesired side effects and reasonable pricing. Therefore, drug substances become more and more complex, therapies become more personalized while overall …
To the complete profileof Belyntic
TQ Therapeutics GmbH (Martinsried, Germany) is a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies. The company’s mission is to develop a transformative cell processing …
To the complete profileof TQ Therapeutics
WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is …
To the complete profileof WMT
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
To the complete profileof Synendos Therapeuthics
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …
To the complete profileof faCellitate
Exit
adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species. Antibody …
To the complete profileof adivo
Exit
PreOmics develops and provides innovative technologies for customers around the world for mass spectrometry (MS) – based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.
To the complete profileof PreOmics
Exit
ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.
To the complete profileof ChromoTek
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal …
To the complete profileof Alentis